SCHEMBL3569002

SCHEMBL3569002

CN(C)CCNC(=O)c1ccc2c([N+](=O)[O-])cc3c(c2c1)C(CCl)CN3

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 2/20 0.45
GSTP1 P09211 1/20 0.40
GSTM2 P28161 1/20 0.40
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
HSP90AA1 P07900 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 1/20 0.37
GAA P10253 2/20 0.37
HTT P42858 2/20 0.37
PARP1 P09874 1/20 0.37
JAK2 O60674 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
KMT2A Q03164 2/20 0.37
CACNA1G O43497 1/20 0.37
MAPKAPK2 P49137 2/20 0.36
THRA P10827 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567311 0.96 SMN1; SMN2 (0.45) SMN1; SMN2MAPTGSTP1GSTM2ALDH1A1
SCHEMBL3566503 0.85 ALDH1A1 (0.39) SMN1; SMN2MAPTGSTP1GSTM2ALDH1A1
SCHEMBL3556964 0.82 VCAM1 (0.41) SMN1; SMN2MAPTALDH1A1HPGDHTT
Hydrochloric Acid SCHEMBL3560929 0.81 KMT2A (0.36) SMN1; SMN2MAPTALDH1A1HPGDKDM4E
SCHEMBL3562739 0.81 CASP6 (0.42) LMNA
SCHEMBL3569084 0.80 PARP1 (0.40) SMN1; SMN2MAPTALDH1A1GAAHTT
SCHEMBL3558765 0.78 VCAM1 (0.41) SMN1; SMN2MAPTALDH1A1HPGDHTT
SCHEMBL3570106 0.76 PARP1 (0.40) SMN1; SMN2MAPTALDH1A1GAAHTT
SCHEMBL13345004 0.76 TSHR (0.38) SMN1; SMN2MAPTALDH1A1KMT2ACACNA1G
SCHEMBL3565777 0.73 KMT2A (0.38) MAPTALDH1A1HPGDKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A SMN1; SMN2 4797/4885MAPT 4792/4885GSTP1 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.